These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 12016876)

  • 1. [Study on liver targeted valaciclovir polybutylcyanoacrylate nanoparticles].
    Zhang Z; He Q
    Yao Xue Xue Bao; 1998 Sep; 33(9):702-6. PubMed ID: 12016876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Preparation of valaciclovir loaded bovine serum albumin nanoparticles surface-modified with glycyrrhizin and its characteristics of targeting to liver].
    Mao S; Hou S; Zhang L; Wei D; Zhang J; Qiao X; He R
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2004 Aug; 21(4):570-4. PubMed ID: 15357434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study on liver targeting and hepatocytes permeable valaciclovir polybutylcyanoacrylate nanoparticles.
    Zhang ZR; He Q
    World J Gastroenterol; 1999 Aug; 5(4):330-333. PubMed ID: 11819460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of diameter of adriamycin polybutylcyanoacrylate nanoparticles on liver targeting].
    Shen LF; Wang X; Wang C; Zhao K; Liu XJ; Shen HJ
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Oct; 31(5):732-6, 741. PubMed ID: 17062941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Preparation of acyclovir-polybutylcyanoacrylate-nanoparticles by emulsion polymerization method].
    Zhang Z; Tian H; He Q
    Hua Xi Yi Ke Da Xue Xue Bao; 1998 Sep; 29(3):329-33. PubMed ID: 10684106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Study on mitoxantrone polycyanoacrylate nanospheres].
    Zhang ZR; Liao GT; Hou SX
    Yao Xue Xue Bao; 1994; 29(7):544-9. PubMed ID: 7976360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Study on liver targeting and sustained release hydroxycamptothecin polybutylcyanoacrylate nanoparticles].
    Zhang ZR; Lu W
    Yao Xue Xue Bao; 1997; 32(3):222-7. PubMed ID: 11327027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Determination of valaciclovir polybutylcyanoacrylate nanoparticles].
    He Q; Zhang Z
    Hua Xi Yi Ke Da Xue Xue Bao; 1998 Sep; 29(3):272-4. PubMed ID: 10684090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans.
    Soul-Lawton J; Seaber E; On N; Wootton R; Rolan P; Posner J
    Antimicrob Agents Chemother; 1995 Dec; 39(12):2759-64. PubMed ID: 8593015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new paediatric formulation of valaciclovir: development and bioequivalence assessment.
    Bastiaans DE; Bartels-Wilmer CM; Colbers AP; Heijens CA; Velthoven-Graafland K; Smeets OS; Vink N; Harbers VE; Warris A; Burger DM
    Arch Dis Child; 2016 Oct; 101(10):971-2. PubMed ID: 27162003
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacokinetics and safety of valaciclovir in children with Epstein-Barr virus illness.
    Simon MW; Fish DN; Deeter RG
    Drugs R D; 2002; 3(6):365-73. PubMed ID: 12516939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of cytomegalovirus infection by valaciclovir after allogeneic bone marrow transplantation from an unrelated donor.
    Mori T; Aisa Y; Shimizu T; Nakazato T; Yamazaki R; Ikeda Y; Okamoto S
    Int J Hematol; 2006 Apr; 83(3):266-70. PubMed ID: 16720561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of valaciclovir dosage reduction in continuous ambulatory peritoneal dialysis patients.
    Stathoulopoulou F; Dhillon S; Thodis H; Stathakis C; Vargemezis V
    Nephron; 2002 May; 91(1):164-6. PubMed ID: 12021536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections.
    Perry CM; Faulds D
    Drugs; 1996 Nov; 52(5):754-72. PubMed ID: 9118821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained-release hydroxycamptothecin polybutylcyanoacrylate nanoparticles as a liver targeting drug delivery system.
    Sun X; Wu F; Lu W; Zhang ZR
    Pharmazie; 2004 Oct; 59(10):791-4. PubMed ID: 15544059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of acyclovir in the cat.
    Owens JG; Nasisse MP; Tadepalli SM; Dorman DC
    J Vet Pharmacol Ther; 1996 Dec; 19(6):488-90. PubMed ID: 8971679
    [No Abstract]   [Full Text] [Related]  

  • 17. Liver targeting and the delayed drug release of the nanoparticles of adriamycin polybutylcyanoacrylate in mice.
    Shen LF; Zhang YD; Shen HJ; Zeng S; Wang X; Wang C; Le Y; Shen H
    Chin Med J (Engl); 2006 Aug; 119(15):1287-93. PubMed ID: 16919188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of valaciclovir.
    MacDougall C; Guglielmo BJ
    J Antimicrob Chemother; 2004 Jun; 53(6):899-901. PubMed ID: 15140857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Risk of CNS adverse effects of aciclovir and valaciclovir. Watch the renal function in treatment of herpes simplex and herpes zoster].
    Helldén A; Bergman U; Dwyer R; Medin C; Molanaei H; Ståhle L; Thylén P; Odar-Cederlöf I
    Lakartidningen; 2007 Jun 13-26; 104(24-25):1916-20. PubMed ID: 17674672
    [No Abstract]   [Full Text] [Related]  

  • 20. [Human recombinant interferon-alpha 2a polybutylcyanoacrylate sustained release lyophilized nanospheres for liver-targeting].
    Lu B; Feng JF; Yang XC
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Jan; 35(1):1-4. PubMed ID: 14981799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.